Selexis SA has entered a new strategic agreement with Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Selexis will provide various cell line-related services that include personnel, laboratory equipment, laboratory space and access to the SUREtechnologyPlatform. As part of the scope of work, Selexis scientists will collaborate with Xencor scientists and project leader...